Approaching First-Line Treatment in PD-L1 CPS <1 HER2-Positive GEA
Zanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.
Zanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.
comments(0)
5-min edit window · permanent after that